<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055635</url>
  </required_header>
  <id_info>
    <org_study_id>DCPT070721</org_study_id>
    <nct_id>NCT05055635</nct_id>
  </id_info>
  <brief_title>Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)</brief_title>
  <acronym>ReRad III</acronym>
  <official_title>ReRad III. Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol aims to determine toxicity and efficacy of re-irradiation for patients with&#xD;
      recurrences from anal cancers with dose-escalated pencil beam proton therapy either&#xD;
      pre-operative for marginally resectable recurrences or as a definitive treatment strategy&#xD;
      (un-resectable, operation declined etc.). The over-all aim is to improve local tumor control&#xD;
      with acceptable side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">July 6, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>12 months</time_frame>
    <description>MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local re-recurrence</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3-5 year FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-5 year FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological evaluation of R0, R1 or R2 resection</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 6 weeks, 1 year, 3 year</time_frame>
    <description>evaluated by NCI-CTCAE v. 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>up to 6 weeks, 1 year, 3 year</time_frame>
    <description>EORTC QLQ-c30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>up to 6 weeks, 1 year, 3 year</time_frame>
    <description>QLQ-CR29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>up to 6 weeks, 1 year, 3 year</time_frame>
    <description>QLQ-ANL27</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>up to 6 weeks, 1 year, 3 year</time_frame>
    <description>LARS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research</measure>
    <time_frame>baseline, end of therapy, 1 year</time_frame>
    <description>cfDNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summed radiotherapy dose volume to organs at risk and correlation to toxicities</measure>
    <time_frame>up to 6 weeks, 1 year, 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate 30-day surgical overall morbidity</measure>
    <time_frame>30-day</time_frame>
    <description>Clavien-Dindo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate 6-month surgical site morbidity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Recurrent Anal Cancer</condition>
  <arm_group>
    <arm_group_label>Doseescalated pencil beam proton therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pencil beam proton therapy</intervention_name>
    <description>Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day</description>
    <arm_group_label>Doseescalated pencil beam proton therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent anal cancer&#xD;
&#xD;
          -  Bioptically verified (squamous cell carcinoma)&#xD;
&#xD;
          -  Available dose plan from primary radiotherapy&#xD;
&#xD;
          -  Previous RT (&gt;30Gy EQD2)&#xD;
&#xD;
          -  Evaluated in MDT-conferences (Herlev, Aarhus)&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases deemed without curative intended treatment options (PET-CT)&#xD;
&#xD;
          -  Unable to undergo MRI, PET-CT&#xD;
&#xD;
          -  Inability to attend full course radiotherapy and follow up in the outpatient clinic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Camilla Kronborg, MD, PhD</last_name>
    <phone>+45 78 45 00 00</phone>
    <email>camkro@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish Centre for Particle Therapy</name>
      <address>
        <city>Aarhus N</city>
        <state>Aarhus</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Kronborg, MD, PhD</last_name>
      <phone>+45 7845 0000</phone>
      <email>camkro@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

